Tarsons Products P/E Ratio
Tarsons Products P/E ratio. Tarsons Products (TARSONS) P/E ratio is not applicable — EPS (TTM) ₹2.69, 1 consecutive loss quarter. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company reported a loss in the most recent quarter. P/E ratio is not meaningful for loss-making periods.
Consecutive Loss Quarters: 1
Current EPS: ₹2.69
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Sept 2026 | -0.06 | 0 | Loss |
| Mar 2026 | 0.79 | 4 | Profit |
| Jun 2026 | -0.27 | -1 | Loss |
| Sept 2025 | 0.62 | 3 | Profit |
| Mar 2025 | 1.92 | 10 | Profit |
| Jun 2025 | 0.34 | 2 | Profit |
| Dec 2025 | 0.95 | 5 | Profit |
| Sept 2024 | 1.93 | 10 | Profit |
Healthcare Peers with Valid P/E Ratios — TARSONS Comparison
Healthcare sector average P/E 51.53, median 29.4 — TARSONS excluded (negative EPS).
Sector Average PE
51.53
Sector Median PE
29.4
Lowest PE
2.0
Profitable Companies
255
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.0 | ₹72 | Low |
| Brooks Laboratories | BROOKS | 2.6 | ₹206 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.3 | ₹54 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.1 | ₹6,355 | Low |
| Dipna Pharmachem | DPL | 4.5 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 4.7 | ₹82 | Low |
| Royal Sense | ROYAL | 4.8 | ₹34 | Low |
| Star Imaging And Path Lab | STARIMAGIN | 5.3 | ₹110 | Low |
| Kabra Drugs | KABRADG | 6.3 | ₹49 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Tarsons Products share price today.
- Check TARSONS market capitalization to track the company's total market size over time.
- Also explore Tarsons Products stock price data download to track price trends across different timeframes.